Inhalation

INH1018

Issue link: https://www.e-digitaleditions.com/i/1032386

Contents of this Issue

Navigation

Page 26 of 31

A list of upcoming conferences, workshops and educational events, with dates, locations and web links for more information and registration. November Inhaled Drug Delivery. November 1-2, 2018. Con- ducted by Management Forum. https://manage m e n t - f o r u m . c o . u k / p r o d u c t / d e t a i l s / 1 7 1 4 / inhaled-drug-delivery PharmSci360. November 4-7, 2018 in Washington, DC. Conducted by the American Association of Phar- maceutical Scientists. www.aaps.org/annual-meet ing-and-conferences/annual-meeting RDD ® Asia 2018. November 14-16, 2018 in Kerala, India. Conducted by RDD Online and Aptar Pharma. www.rddonline.com/rdd/rdd.php?id=16 December Drug Delivery to the Lungs 2018. December 12-14, 2018 in Edinburgh, UK. Conducted by the Aerosol Society. https://aerosol-soc.com/events/ddl2018 CALENDAR To be featured at AAPS PharmSci360 and DDL2018 If you are attending AAPS PharmSci 360 or DDL2018, please visit Inhalation's advertisers. See the following link for information on the products and services they will be exhibiting: https://www.inhalationmag.com/digital_inh/ INH_upcoming/INH_new_upcoming.html To be featured at AAPS PharmSci360 and DDL2018 Development and manufacturing for novel respiratory products Recipharm and Sanofi have completed the trans- fer of Sanofi's Holmes Chapel, UK site to leading pharmaceutical CDMO, Recipharm. e new facil- ity, which includes devel- opment and manufactur- ing capabilities for novel respiratory products, com- plements the inhalation development expertise o ered by the Recipharm team in Research Triangle Park, North Carolina, US. e prime technologies manufactured at the facility include metered dose inhalers and nasal sprays. It also houses several development suites speci cally for dry powder and other inhalation technologies. Recipharm Sweden: + 46 8 602 52 00 www.recipharm.com Product development and compliant manufacture Hovione o ers development and compliant manufac- ture of innovative new drugs and niche generic active pharmaceutical ingredient (API) products. Hovione also supports highly potent compounds and o ers propri- etary product development and licensing opportunities for drug products. e company undertakes formulation development and clinical supply of nal dosage forms to Phase II. With strong expertise in pulmonary delivery, Hovione also o ers APIs for inhala tion, DPI devices and particle engineer ing services. Hovione Portugal: +351 21 982 9000 www.hovione.com Inhalation OCTOBER 2018 25 SUBSCRIBE TODAY www.inhalationmag.com

Articles in this issue

Links on this page

view archives of Inhalation - INH1018